Clearside Biomedical, Inc. (NASDAQ:CLSD) has earned an average recommendation of “Hold” from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $21.25.

A number of brokerages have weighed in on CLSD. ValuEngine downgraded shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. TheStreet downgraded shares of Clearside Biomedical from a “c-” rating to a “d” rating in a report on Friday, August 11th. Cowen reissued a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, October 25th. Finally, Zacks Investment Research raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th.

Shares of Clearside Biomedical (CLSD) opened at $5.97 on Thursday. Clearside Biomedical has a 1-year low of $5.44 and a 1-year high of $15.05. The company has a quick ratio of 4.57, a current ratio of 4.57 and a debt-to-equity ratio of 0.15.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.17). Clearside Biomedical had a negative net margin of 17,684.07% and a negative return on equity of 90.72%. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.01 million. research analysts forecast that Clearside Biomedical will post -2.33 EPS for the current fiscal year.

In other Clearside Biomedical news, insider Daniel H. White sold 16,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $7.57, for a total transaction of $121,120.00. Following the sale, the insider now owns 486,935 shares in the company, valued at approximately $3,686,097.95. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Clay Thorp sold 35,000 shares of the business’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $8.57, for a total value of $299,950.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,000 shares of company stock worth $1,126,955. Corporate insiders own 20.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC raised its holdings in Clearside Biomedical by 4.0% during the 2nd quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock worth $135,000 after buying an additional 563 shares during the period. Bank of New York Mellon Corp raised its holdings in Clearside Biomedical by 10.8% during the 1st quarter. Bank of New York Mellon Corp now owns 34,823 shares of the company’s stock worth $277,000 after buying an additional 3,404 shares during the period. Marshall Wace North America L.P. raised its holdings in Clearside Biomedical by 1.9% during the 2nd quarter. Marshall Wace North America L.P. now owns 218,960 shares of the company’s stock worth $1,971,000 after buying an additional 4,010 shares during the period. TIAA CREF Investment Management LLC raised its holdings in Clearside Biomedical by 30.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 19,257 shares of the company’s stock worth $153,000 after buying an additional 4,527 shares during the period. Finally, Nationwide Fund Advisors raised its holdings in Clearside Biomedical by 118.3% during the 2nd quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after buying an additional 6,343 shares during the period. Hedge funds and other institutional investors own 51.73% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Clearside Biomedical, Inc. (CLSD) Receives Average Rating of “Hold” from Analysts” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/07/clearside-biomedical-inc-clsd-receives-average-rating-of-hold-from-analysts.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.